Collaboration agreement with MolecularMD


Our attorneys advised longtime client Novartis in a collaboration agreement with MolecularMD Corporation to develop a companion diagnostic test to aid in the identification of Ph+ chronic myelogenous leukemia (CML) patients who have achieved durable minimal residual disease with nilotinib (Tasigna®), and to provide molecular monitoring for patients during treatment-free remission. MolecularMD Corporation is a private company that develops and commercializes specialty molecular diagnostics for oncology applications.


Email Disclaimer